JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $81

Benzinga · 20h ago
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $79 to $81.